obiadminpharma

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform.

Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform. OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential …

Investigation of the impact of Globo-H expression on the progression of gastric cancer

OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424

SOLID TUMOR PATIENTS WITH HIGH GLOBO H OR AKR1C3 EXPRESSION WILL BE ENROLLED. TAIPEI, Taiwan, January 24, 2022 — OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that …

Announcement to approve the lifting of non-competition restrictions for directors at the 2021 Annual General Meeting

1. Date of the shareholders’ meeting resolution: July 16, 2021 2. Name and title of the managerial officer with permission to engage in competitive conduct: Independent Director: Howard Lee Director: …

Announcement on the elected Independent Director at the 2021 Annual General Meeting

1. Date of occurrence of the change: July 16, 2021 2. Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): independent director …

Announcement of resolution items from 2021 Annual General Meeting

1. Date of the shareholders’ meeting: July 16, 2021 2. Important resolutions I. Profit distribution/deficit compensation: Resolution on acknowledgment of the 2020 Earnings Distribution Loss Off-setting 3. Important resolutions II. …

OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities

Contents: 1.Date of institutional investor conference: Dec 21, 2020 2.Time of institutional investor conference: 14:30:00 NST 3.Location of institutional investor conference: Masterlink Securities (Address: No.97-11, Sec. 2, Dunhua S. Rd., …

OBI licensed the Intellectual Property Right of Global Aesthetic Medicine to a designated company

Contents: 1.Date of occurrence of the event: Dec 04, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4.Reciprocal shareholding ratios: …

OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (supplement base date)

1.Type of merger and acquisition (e.g. merger, spin-off, acquisition, or share transfer): Share transfer 2.Date of occurrence of the event: Nov 27, 2020 3.Names of companies participating in the merger …

OBI received the reply from FDA about the Investigational Device Exemption (IDE) of Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424

1. Date of occurrence of the event: Nov 23, 2020 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): head office 4. …